Home › Focal Segmental Glomerulosclerosis › Illinois
Focal Segmental Glomerulosclerosis clinical trials in Illinois
4 studies for Focal Segmental Glomerulosclerosis are looking for participants at sites in Illinois.
Cities in Illinois
A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease
- Northwestern Memorial Hospital- Site Number : 8400014, Chicago
- Nephrology Associates of Northern Illinois and Indiana (NANI) - Hinsdale- Site Number : 8400017, Hinsdale
RecruitingPhase 2
Ages 16 to 75 · All sexes · Updated Sep 23, 2026 · NCT06500702A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
- Northwestern University, Chicago
- Endeavor Health, Evanston
- and 1 more
RecruitingPhase 3
Ages 12 and older · All sexes · Updated Sep 17, 2026 · NCT07220083NEPTUNE Match Study
- John H. Stroger, Jr., Hospital of Cook County, Chicago
Recruiting
Ages 1 to 80 · All sexes · Updated Jun 10, 2026 · NCT04571658Nephrotic Syndrome Study Network
- John Stroger Cook County Hospital, Chicago
RecruitingObservational study
Up to age 80 · All sexes · Updated Jun 10, 2026 · NCT01209000From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.